A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial

BACKGROUND: high recurrence rates of up to 75% within 2 years in pancreatic ductal adenocarcinoma (PDAC) patients resected for cure indicate a high medical need for clinical prediction tools and patient specific treatment approaches. Addition of the EGFR inhibitor erlotinib to adjuvant chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoyer, K., Hablesreiter, R., Inoue, Y., Yoshida, K., Briest, F., Christen, F., Kakiuchi, N., Yoshizato, T., Shiozawa, Y., Shiraishi, Y., Striefler, J.K., Bischoff, S., Lohneis, P., Putter, H., Blau, O., Keilholz, U., Bullinger, L., Pelzer, U., Hummel, M., Riess, H., Ogawa, S., Sinn, M., Damm, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054140/
https://www.ncbi.nlm.nih.gov/pubmed/33862582
http://dx.doi.org/10.1016/j.ebiom.2021.103327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054140/
https://www.ncbi.nlm.nih.gov/pubmed/33862582
http://dx.doi.org/10.1016/j.ebiom.2021.103327

Ejemplares similares